Literature DB >> 36253524

Utility of cell-free DNA from bronchial washing fluid in diagnosis and genomic determination for radiology-suspected pulmonary nodules.

Xinyu Zhang1, Zhuo Yu2, Yaping Xu3, Yencheng Chao1, Qin Hu1, Chun Li1, Maosong Ye1, Xiuli Zhu3, Liang Cui3, Jing Bai3, Yuhua Gong3, Yanfang Guan3, Min Zhou4, Jian'an Huang5, Hua Zhang6, Tao Ren7, Qian Shen8, Kai Wang9, Yingyong Hou1, Xuefeng Xia3, Xingxiang Pu10, David P Carbone11, Xin Zhang12.   

Abstract

BACKGROUND: Bronchial washing fluid (BWF) is a less-invasive specimen. Due to the limited sensitivity of BWF cellular component diagnosis, the aim of this study was to explore the potential role of BWF supernatant as a source of liquid biopsy of lung cancer.
METHODS: This prospective study enrolled 76 suspected and 5 progressed lung cancer patients. Transbronchial biopsy tissues, BWF supernatant (BWF_Sup) and BWF precipitant (BWF_Pre) were tested by a targeted panel of 1021 genes.
RESULTS: BWF_Sup cell-free DNA (cfDNA) was superior to tissue biopsy and BWF_Pre in determining mutational allele frequency, tumour mutational burden, and chromosomal instability. Moreover, BWF_Sup and BWF_Pre achieved comparable efficacy to tissue samples in differentiating malignant and benign patients, but only BWF_Sup persisted differentiated performance after excluding 55 malignancies pathologically diagnosed by bronchoscopic biopsy. Among 67 malignant patients, 82.1% and 71.6% of tumour-derived mutations (TDMs) were detected in BWF_Sup and BWF_Pre, respectively, and the detectability of TDMs in BWF_Sup was independent of the cytological examination of BWF. BWF_Sup outperformed BWF_Pre in providing more subclonal information and thus might yield advantage in tracking drug-resistant markers.
CONCLUSIONS: BWF_Sup cfDNA is a reliable medium for lung cancer diagnosis and genomic profiles and may provide important information for subsequent therapeutic regimens.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Year:  2022        PMID: 36253524     DOI: 10.1038/s41416-022-01969-2

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   9.075


  46 in total

1.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

Review 2.  The diverse origins of circulating cell-free DNA in the human body: a critical re-evaluation of the literature.

Authors:  Janine Aucamp; Abel J Bronkhorst; Christoffel P S Badenhorst; Piet J Pretorius
Journal:  Biol Rev Camb Philos Soc       Date:  2018-04-14

3.  A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma.

Authors:  Karen L Reckamp; Vladislava O Melnikova; Chris Karlovich; Lecia V Sequist; D Ross Camidge; Heather Wakelee; Maurice Perol; Geoffrey R Oxnard; Karena Kosco; Peter Croucher; Errin Samuelsz; Cecile Rose Vibat; Shiloh Guerrero; Jennifer Geis; David Berz; Elaina Mann; Shannon Matheny; Lindsey Rolfe; Mitch Raponi; Mark G Erlander; Shirish Gadgeel
Journal:  J Thorac Oncol       Date:  2016-07-25       Impact factor: 15.609

Review 4.  Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.

Authors:  Jason D Merker; Geoffrey R Oxnard; Carolyn Compton; Maximilian Diehn; Patricia Hurley; Alexander J Lazar; Neal Lindeman; Christina M Lockwood; Alex J Rai; Richard L Schilsky; Apostolia M Tsimberidou; Patricia Vasalos; Brooke L Billman; Thomas K Oliver; Suanna S Bruinooge; Daniel F Hayes; Nicholas C Turner
Journal:  J Clin Oncol       Date:  2018-03-05       Impact factor: 44.544

5.  Circulating mutant DNA to assess tumor dynamics.

Authors:  Frank Diehl; Kerstin Schmidt; Michael A Choti; Katharine Romans; Steven Goodman; Meng Li; Katherine Thornton; Nishant Agrawal; Lori Sokoll; Steve A Szabo; Kenneth W Kinzler; Bert Vogelstein; Luis A Diaz
Journal:  Nat Med       Date:  2007-07-31       Impact factor: 53.440

6.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

7.  Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Authors:  Manabu Soda; Young Lim Choi; Munehiro Enomoto; Shuji Takada; Yoshihiro Yamashita; Shunpei Ishikawa; Shin-ichiro Fujiwara; Hideki Watanabe; Kentaro Kurashina; Hisashi Hatanaka; Masashi Bando; Shoji Ohno; Yuichi Ishikawa; Hiroyuki Aburatani; Toshiro Niki; Yasunori Sohara; Yukihiko Sugiyama; Hiroyuki Mano
Journal:  Nature       Date:  2007-07-11       Impact factor: 49.962

8.  Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer.

Authors:  Alexa B Schrock; Allison Welsh; Jon H Chung; Dean Pavlick; Eric H Bernicker; Benjamin C Creelan; Brady Forcier; Jeffrey S Ross; Philip J Stephens; Siraj M Ali; Ibiayi Dagogo-Jack; Alice T Shaw; Tianhong Li; Sai-Hong Ignatius Ou; Vincent A Miller
Journal:  J Thorac Oncol       Date:  2018-10-24       Impact factor: 15.609

9.  Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.

Authors:  Jeffrey C Thompson; Stephanie S Yee; Andrea B Troxel; Samantha L Savitch; Ryan Fan; David Balli; David B Lieberman; Jennifer D Morrissette; Tracey L Evans; Joshua Bauml; Charu Aggarwal; John A Kosteva; Evan Alley; Christine Ciunci; Roger B Cohen; Stephen Bagley; Susan Stonehouse-Lee; Victoria E Sherry; Elizabeth Gilbert; Corey Langer; Anil Vachani; Erica L Carpenter
Journal:  Clin Cancer Res       Date:  2016-09-06       Impact factor: 12.531

10.  An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.

Authors:  Aaron M Newman; Scott V Bratman; Jacqueline To; Jacob F Wynne; Neville C W Eclov; Leslie A Modlin; Chih Long Liu; Joel W Neal; Heather A Wakelee; Robert E Merritt; Joseph B Shrager; Billy W Loo; Ash A Alizadeh; Maximilian Diehn
Journal:  Nat Med       Date:  2014-04-06       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.